What is the price-to-earnings ratio of Biotest?
The price-earnings ratio of Biotest is currently 2.55.
Biotest P/S 2024
Biotest P/S
2.55
Ticker
BIO.DE
ISIN
DE0005227201
WKN
522720
As of Sep 29, 2024, Biotest's P/S ratio stood at 2.55, a 4.08% change from the 2.45 P/S ratio recorded in the previous year.
The Biotest P/S history
Biotest Aktienanalyse
What does Biotest do?
Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Biotest's P/S Ratio
Biotest's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Biotest's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Biotest's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Biotest’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Biotest stock
How has the price-earnings ratio of Biotest changed compared to last year?
The price-to-earnings ratio of Biotest has increased by 4.08% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Biotest high compared to other companies?
Yes, the price-to-earnings ratio of Biotest is high compared to other companies.
How does an increase in the price-earnings ratio of Biotest affect the company?
An increase in the price-earnings ratio of Biotest would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Biotest affect the company?
A decrease in the price-earnings ratio of Biotest would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Biotest?
Some factors that influence the price-earnings ratio of Biotest are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Biotest pay?
Over the past 12 months, Biotest paid a dividend of 0.05 EUR . This corresponds to a dividend yield of about 0.12 %. For the coming 12 months, Biotest is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biotest?
The current dividend yield of Biotest is 0.12 %.
When does Biotest pay dividends?
Biotest pays a quarterly dividend. This is distributed in the months of June, June, June, September.
How secure is the dividend of Biotest?
Biotest paid dividends every year for the past 2 years.
What is the dividend of Biotest?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biotest located?
Biotest is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biotest kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biotest from 9/4/2017 amounting to 0.05 EUR, you needed to have the stock in your portfolio before the ex-date on 8/31/2017.
When did Biotest pay the last dividend?
The last dividend was paid out on 9/4/2017.
What was the dividend of Biotest in the year 2023?
In the year 2023, Biotest distributed 0 EUR as dividends.
In which currency does Biotest pay out the dividend?
The dividends of Biotest are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biotest
Our stock analysis for Biotest Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotest Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
